Impact of orlistat-induced weight loss on diastolic function and heart rate variability in severely obese subjects with diabetes.
Objective. Determine the impact of Orlistat-induced weight loss on metabolic profile and cardiovascular function in severely obese patients with type 2 diabetes. Methods. Twenty-nine patients were randomized either to a nonplacebo control group or to a treatment group with Orlistat thrice a day. Metabolic profile, anthropometric parameters, heart rate variability indices, and echocardiographic variables were measured before and after a 12-week treatment period. Results. Treatment with Orlistat induced a modest but significant weight loss compared to controls (3.7 ± 3.0 versus 0.5 ± 2.2 kg, resp.; P = .003). There was significant decrease in fasting glycemia (7.9 ± 3.0 versus 6.7 ± 2.2 mmol/L; P = .03) and significant improvements in left ventricular diastolic function (P = .03) and in the sympathovagal balance (LF/HF ratio) (P = .04) in the Orlistat group. Conclusion. These results suggest that a modest weight loss improves fasting glycemia, left ventricular diastolic function, and sympathovagal balance in severely obese patients with type 2 diabetes.
Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), 2725 Chemin Ste-Foy, QC, Canada G1V 4G5.
Julie
J
Martin
Carmen
C
Paquette
Simon
S
Marceau
Frédéric-Simon
FS
Hould
Stéfane
S
Lebel
Serge
S
Simard
Jean-Gaston
JG
Dumesnil
Paul
P
Poirier
Am J Cardiol. 1991 Jul 1;68(1):95-8
1829321
Surg Obes Relat Dis. 2009 Nov-Dec;5(6):648-52
19833561
Am J Cardiol. 1987 Apr 15;59(9):956-60
2952002
Clin Chem. 1972 Jun;18(6):499-502
4337382
Diabetes Care. 2004 Jan;27(1):33-40
14693963
Metabolism. 2003 Aug;52(8):1056-61
12898473
Am J Cardiol. 1995 Dec 1;76(16):1194-7
7484912
J Am Soc Echocardiogr. 2002 Oct;15(10 Pt 2):1226-31
12411909
Can J Cardiol. 1995 May;11(5):391-5
7750035
Circulation. 2006 Feb 14;113(6):898-918
16380542
Circulation. 2004 Nov 2;110(18):2952-67
15509809
J Hypertens. 1998 Dec;16(12 Pt 2):2013-7
9886891
Exp Biol Med (Maywood). 2001 May;226(5):440-5
11393172
Circulation. 2003 Feb 4;107(4):565-70
12566367
Am J Cardiol. 1999 Apr 15;83(8):1242-7
10215292
Am J Physiol. 1991 Dec;261(6 Pt 2):R1418-23
1750566
Diabetes Care. 1998 Aug;21(8):1288-94
9702435
Acta Med Scand. 1979;205(5):367-73
443075
Arch Fam Med. 2000 Feb;9(2):160-7
10693734
Obes Res. 2003 Sep;11(9):1040-7
12972673
J Intern Med. 2000 Sep;248(3):245-54
10971792
N Engl J Med. 1988 Apr 28;318(17):1077-83
3352710
Am J Cardiol. 1994 May 1;73(12):918-21
8184827
Diabetologia. 2005 Jul;48(7):1258-63
15937670
Eur Heart J. 1996 Mar;17(3):354-81
8737210
Arch Intern Med. 2010 Jan 25;170(2):146-54
20101009
J Am Coll Cardiol. 2009 Aug 18;54(8):718-26
19679250
Am J Cardiol. 2005 Jun 15;95(12):1521-4
15950589
Diabetes Obes Metab. 2000 Jun;2(3):175-87
11220553
JAMA. 2003 Jan 8;289(2):194-202
12517230
Int J Obes Relat Metab Disord. 2000 Mar;24(3):306-13
10757623
Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):24-30
15871847
Obes Res. 1998 Sep;6 Suppl 2:51S-209S
9813653
JAMA. 1999 Jan 20;281(3):235-42
9918478
Surgery. 1990 Oct;108(4):809-18; discussion 818-20
2218895
Obes Res. 2001 Oct;9(10):637-43
11595781
Diabetes Care. 2001 Jan;24(1):5-10
11194240
Br J Nutr. 2006 Nov;96(5):956-64
17092388
Lancet. 1998 Jul 18;352(9123):167-72
9683204
J Endocrinol Invest. 2003 Feb;26(2):138-42
12739741
Obes Surg. 2001 Oct;11(5):552-8
11594094